Researchers investigated the role of interleukin-1 inhibition in improving glycemic and inflammatory parameters in patients with rheumatoid arthritis and type 2 diabetes.
Researchers assessed the risk for rheumatoid arthritis in patients receiving antibiotics.
![The clustering of RA among family members suggests a strong genetic link, supported by the identification of specific alleles within defined loci in the human leukocyte antigen (HLA) system that are associated with increased risk for the development of anticitrullinated protein antibody-positive and anticitrullinated protein antibody-negative RA. [3]](https://1fxghyessyy2gaob23ygwzph-wpengine.netdna-ssl.com/wp-content/uploads/sites/18/2019/01/thinkstockphotos15641636741_1010901-544x306.jpg)
Researchers examined the effects of HLA-B27 and HLA-DRB1 alleles on the intestinal microbiome of healthy individuals.
The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
The model improves anti-TNF drug selection and the effect of genetic markers across multiple cohorts.
![Comprehensive laboratory evaluation is important if blood transfusion is expected, to screen for antirheumatic drug side effects, and to assess medical comorbidities. [3] The results of these tests should be shared with the surgical team to reduce surgical morbidity and mortality.](https://1fxghyessyy2gaob23ygwzph-wpengine.netdna-ssl.com/wp-content/uploads/sites/18/2019/01/thinkstockphotos454249703101_939914-544x306.jpg)
This is the first study to examine the real-world outcome of the management of RA using neutrophil-lymphocyte ratio.
Results of an investigational US pilot study have shown that a proprietary bioelectronic microregulator device, manufactured by SetPoint Medical, can benefit patients with rheumatoid arthritis.
Upadacitinib monotherapy resulted in improvements in clinical and functional outcomes vs continuing methotrexate in a population of methotrexate inadequate-responders with active RA.
Study compared efficacy and safety of filgotinib with and without methotrexate in patients with rheumatoid arthritis who were naive to methotrexate therapy.
Researchers sought to determine whether exposure to methotrexate for rheumatoid arthritis may lead to interstitial lung disease.
